Pitcairn Co. Has $498,000 Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Pitcairn Co. increased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 8.7% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,532 shares of the medical research company’s stock after acquiring an additional 203 shares during the period. Pitcairn Co.’s holdings in IQVIA were worth $498,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of IQV. Massachusetts Financial Services Co. MA raised its stake in shares of IQVIA by 5.6% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 142,249 shares of the medical research company’s stock worth $27,953,000 after purchasing an additional 7,546 shares in the last quarter. Headlands Technologies LLC raised its position in IQVIA by 397.0% during the fourth quarter. Headlands Technologies LLC now owns 1,675 shares of the medical research company’s stock worth $329,000 after acquiring an additional 1,338 shares in the last quarter. Geode Capital Management LLC lifted its stake in IQVIA by 1.9% in the fourth quarter. Geode Capital Management LLC now owns 4,175,524 shares of the medical research company’s stock valued at $818,315,000 after acquiring an additional 77,981 shares during the last quarter. HighPoint Advisor Group LLC grew its position in shares of IQVIA by 22.7% in the 4th quarter. HighPoint Advisor Group LLC now owns 2,133 shares of the medical research company’s stock valued at $428,000 after acquiring an additional 395 shares during the period. Finally, Franklin Resources Inc. increased its stake in shares of IQVIA by 4.7% during the 4th quarter. Franklin Resources Inc. now owns 525,489 shares of the medical research company’s stock worth $103,264,000 after purchasing an additional 23,682 shares during the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Trading Down 7.8 %

IQV opened at $154.63 on Friday. The stock has a market capitalization of $27.26 billion, a price-to-earnings ratio of 20.62, a P/E/G ratio of 1.99 and a beta of 1.46. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a twelve month low of $154.35 and a twelve month high of $252.88. The company has a 50-day simple moving average of $189.67 and a 200 day simple moving average of $203.82.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently commented on IQV. Bank of America reduced their price target on IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a report on Friday, December 13th. William Blair reiterated an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. Morgan Stanley increased their price target on IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a research note on Tuesday, February 11th. Citigroup reduced their price objective on shares of IQVIA from $225.00 to $210.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. Finally, Robert W. Baird dropped their price objective on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 21st. Five analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $249.05.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.